More Videos
- Sam Waksal: "Moving On Up" To The East Side
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Merck Offering To Help Patients—Or Itself?
- GM, Ford & Chrysler CEOs Take Their Medicine
- Stop Trading!: Cheap-Oil Plays
- California's Budget Crisis: Just Part Of "Cuckoo Land"?
- Is "Dexter" Hero Of Our Times?
- Stock Picker: No Place Like Home (Builders)
- Sumner Redstone's Next Step Is Juggling Debt
- Najarian on Options: A Bullish Move on BP
- The Investor "Revolt" Over Modified Loans
- Bowyer: NBER: the Official Sponsor of the 2007 Recession
- BEHIND THE MONEY: Goldman Can't Let Go
- Small Players Vie for ‘Green Car’ Loans
- Bailout Monitor Sees Lack of a Coherent Plan
- Pros: Searching the Gloom ... Bright Spot in Japan
- Putting a Value on a C.E.O.
- Where the Layoffs Are—Is Your Firm on the List?
- Treasurys Mostly Higher Despite Stock Gains
- BofA to Cut 10,000 Investment Banking Jobs
- GE to Maintain Dividend, Streamline Finance Arm
- Delta Air to Reduce Capacity By 6 to 8 Percent
Text Size 
 |
CNBC.com |
Carl Icahn apparently loves a good fight and to throw punches in plain sight. If nothing else, it certainly keeps things interesting for those of us who remain focused on stuff outside the financial sector.
Check out Icahn's latest one-paragraph missive to Bristol-Myers Squibb[BMY
Loading...
()
] CEO Jim Cornelius.
The best line of a few good ones: "...your hostile tender of $62...seems absurd."
Icahn underlined hostile, not me.
The letter, which was released by ImClone [IMCL
Loading...
()
]Tuesday evening, was prompted by Bristol upping its original $60-a-share offer by two bucks on Monday night. That's despite (or in spite of?) Icahn's claim of a $70 offer from a still-mystery bidder.
Since Icahn got involved with ImClone and new management took over at both companies, IMCL and BMY had made great strides toward improving what some insiders reportedly saw as a somewhat strained relationship. The two are partners on the blockbuster cancer drug Erbitux.
As the war of words escalates, one has to wonder if these two do end up getting together how they'll go about mending fences this time. Maybe Icahn's feeling that confident about the outcome of the mystery bidder's due diligence which he says will be done this weekend. Or is it just typical corporate gamesmanship?
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes